Compare PUBM & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PUBM | SLGL |
|---|---|---|
| Founded | 2006 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.6M | 247.1M |
| IPO Year | 2020 | 2016 |
| Metric | PUBM | SLGL |
|---|---|---|
| Price | $9.70 | $77.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $12.43 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 591.3K | 50.6K |
| Earning Date | 05-07-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $282,926,000.00 | N/A |
| Revenue This Year | $3.44 | N/A |
| Revenue Next Year | $7.86 | $223.84 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.15 | $0.62 |
| 52 Week High | $13.26 | $97.97 |
| Indicator | PUBM | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 66.67 | 52.11 |
| Support Level | $7.92 | $70.31 |
| Resistance Level | $11.08 | $84.75 |
| Average True Range (ATR) | 0.41 | 5.57 |
| MACD | 0.03 | 0.21 |
| Stochastic Oscillator | 87.77 | 55.88 |
PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.